Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences | ||
By: GlobeNewswire - 22 Nov 2022 | Back to overview list |
|
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today that it will take part in two fireside chats, the first at the Piper Sandler 34th Annual Healthcare Conference, to be held November 29-December 1 in New York, and the second at the JMP Securities Hematology & Oncology Summit, to be held virtually December 6-7. During the fireside chats Cue Biopharma will provide an updated corporate overview highlighting recent data from its lead clinical program, CUE-101, representative of the IL-2-based CUE-100 series, currently being evaluated in a Phase 1 trial as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with HPV+ recurrent/metastatic head and neck cancer. The discussion will also include the Company’s second clinical asset from the CUE-100 series, CUE-102, currently being evaluated in a Phase 1 trial for the treatment of Wilms’ Tumor 1 (WT1) positive cancers, as well as other pipeline and platform developments. Piper Sandler 34th Annual Healthcare Conference JMP Securities Hematology & Oncology Summit Live and archived webcasts of the fireside chats will be available on the Events page in the Investors and Media section of the Company’s website at www.cuebiopharma.com. The webcasts will be archived for 30 days. Investor Contact Media Contact |
||
|
||
Copyright 2022 GlobeNewswire | Back to overview list |